Intellia Therapeutics (NTLA) Projected to Post Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.99) per share and revenue of $12.1730 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $13.58 on Wednesday. The company has a fifty day moving average price of $11.60 and a 200-day moving average price of $12.99. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -3.18 and a beta of 2.10. Intellia Therapeutics has a 1 year low of $5.90 and a 1 year high of $28.25.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. JonesTrading lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 11th. Wells Fargo & Company dropped their price target on Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Wolfe Research restated a “peer perform” rating on shares of Intellia Therapeutics in a research note on Wednesday, November 12th. HC Wainwright lifted their target price on Intellia Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, January 28th. Finally, KeyCorp set a $25.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, January 28th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $17.48.

Insider Buying and Selling

In other news, CEO John M. Leonard sold 34,146 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the transaction, the chief executive officer directly owned 1,013,339 shares in the company, valued at $9,332,852.19. The trade was a 3.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Birgit C. Schultes sold 8,508 shares of Intellia Therapeutics stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the sale, the executive vice president directly owned 98,533 shares of the company’s stock, valued at $907,488.93. This represents a 7.95% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 53,051 shares of company stock valued at $488,600. Corporate insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Large investors have recently modified their holdings of the company. AQR Capital Management LLC raised its holdings in Intellia Therapeutics by 154.1% during the 1st quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock valued at $646,000 after buying an additional 55,118 shares during the last quarter. Woodline Partners LP purchased a new position in shares of Intellia Therapeutics in the first quarter valued at about $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Intellia Therapeutics by 8.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock valued at $3,709,000 after acquiring an additional 38,521 shares during the last quarter. Creative Planning boosted its holdings in shares of Intellia Therapeutics by 12.9% during the second quarter. Creative Planning now owns 33,102 shares of the company’s stock worth $310,000 after purchasing an additional 3,795 shares during the period. Finally, Cetera Investment Advisers grew its stake in shares of Intellia Therapeutics by 47.4% in the second quarter. Cetera Investment Advisers now owns 33,532 shares of the company’s stock worth $315,000 after purchasing an additional 10,785 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.